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Cysteine cathepsins are proteases which are naturally present in the human 
body, taking part in various physiological processes such as cell signaling, 
proliferation or bone remodeling. However, their dysregulation leads to serious 
disorders. An aberrant activity of cysteine cathepsins is present in diseases like 
cancer, osteoporosis, neurodegenerative disorders or autoimmune diseases. 
Therefore, these enzymes can serve as valuable diagnostic or therapeutic 
targets. Rhodesain is a parasitic protease produced by Trypanosoma brucei 
rhodesiense and essential for its survival. This enzyme shares a high homology 
with human cysteine cathepsin L. Inhibition of rhodesain can be a potential 
treatment of African trypanosomiasis, also known as sleeping sickness.  
 
Inhibitory potency of several compounds against the target enzymes was 
assayed spectrophotometrically or fluorometrically and the results were 
evaluated by using linear or non-linear regression. Determination of a Michaelis-
Menten constant for rhodesain under specific assay conditions was also 
performed. Some potent inhibitors of tested proteases have been identified and 
additionally, a potential activity-based probe was investigated for its applicability 
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Cysteinové katepsíny jsou proteázy, které se přirozeně vyskytují v lidském těle a 
účastní se mnoha fyziologických procesů, jako je například buněčná signalizace, 
proliferace nebo kostní přestavba. Jejich dysregulace ale může vést k vážným 
poruchám. Abnormální aktivita cysteinových katepsínů je přítomna u 
onemocnění zahrnujících osteoporózu, nádorová, neurodegenerativní nebo 
autoimunitní onemocnění. Tyto enzymy proto mohou sloužit jako hodnotné 
diagnostické nebo terapeutické cíle. Rodesain je parazitická proteáza 
produkovaná Trypanosomou brucei rhodesiense a je nezbytná pro její přežití. 
Tento enzym sdílí vysokou homologii s lidským cysteinovým katepsinem L. 
Inhibice rodesainu může být potenciální léčbou africké trypanosomiázy, také 
známé jako spavé nemoci.  
 
Inhibiční potenciál mnoha sloučenin proti cílovým enzymům byl testován 
spektrofotometricky nebo fluorometricky a výsledky byly hodnoceny za použití 
lineární či nelineární regrese. Také bylo provedeno stanovení konstanty 
Michaelise a Mentenové pro rodesain za specifických testovacích podmínek. 
Bylo identifikováno pár silných inhibitorů testovaných proteáz a dodatečně byla 
testována použitelnost potenciální sondy značící aktivní enzym v elektroforéze v 
polyakrylamidovém gelu v přítomnosti dodecylsíranu sodného. 
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ABP activity-based probe 
AMC 7-amino-4-methylcoumarin 
APS ammonium persulfate 
Arg arginine 
Brij 35 polyethylene lauryl ether 
Cat B  cathepsin B 
Cat K cathepsin K 
Cat L cathepsin L 






EDTA ethylenediaminetetraacetic acid 
HEK human embryonic kidney 
[I] inhibitor concentration 
I inhibitor 
IC50  half maximal inhibitory concentration 
Ki  inhibitory constant 
kinact  inactivation rate constant 
kinact/Ki second-order inactivation rate constant 
KM  Michaelis-Menten constant 
kobs first-order rate constant 
koff dissociation constant 
kon association constant 
kon’ apparent association constant 
Leu leucine 
MES 2-(N-morpholino)ethanesulfonic acid 
NI no inhibition 





RA remaining enzyme activity 
Rhod rhodesain 
[S]  substrate concentration 
S substrate 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
T. b. Trypanosoma brucei 
TRIS tris(hydroxymethyl)aminomethane 
Triton polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether 
UV ultraviolet 
v0 reaction rate in the absence inhibitor 
Val valine 
vi initial velocity of product formation 
Vmax maximal reaction velocity 
vs  steady-state reaction rate in the presence of inhibitor 





Proteases, proteinases or peptidases are enzymes that cleave amide bonds in a 
polypeptide chain via hydrolysis (Siklos et al. 2015). That means that with the use 
of water, they degrade proteins into smaller polypeptides or single amino acids. 
Not only are they involved in the metabolism of ingested food, where enzymes 
have to be able to breakdown a wide range of substrates. Their activity is often 
narrowed to highly specific processes such as cell signaling, blood coagulation 
and fibrinolysis, or the complement system (Copeland 2005). Based on the 
active-site catalytic residue, they are divided into seven groups (Barrett et al. 
2013). All enzymes of this thesis belong to the group of cysteine proteases.  
 
Cysteine cathepsins are ubiquitously expressed in human as well as in all other 
living organisms, including viruses (Otto and Schirmeister 1997). Their exact 
function is essential for various processes and dysregulation is connected with 
diseases such as cancer, osteoporosis, arthritis, neurodegenerative diseases, 
obesity and many more (Kramer et al. 2017). 
 
Rhodesain is a cathepsin L-like protease utilized by Trypanosoma brucei 
rhodesiense. This parasite is the agent causing human African trypanosomiasis, 
also known as sleeping sickness, which is transmitted by a bite of the vector, the 
tsetse fly. Not only is rhodesain required for invasion of the parasite, it is also 
needed for its survival (Ettari et al. 2016).  
 
These proteins can serve as valuable diagnostic and therapeutic targets. 
Therefore, identification on new inhibitors and activity-based probes would be of 





3. AIMS AND OBJECTIVES 
 
The aim of this work is to identify and evaluate new enzyme inhibitors and  
activity-based probes in vitro. Target enzymes are human cathepsins B, K, L and 
S and a parasitic enzyme, rhodesain, all belonging to a group of cysteine 
proteases. These enzymes, involved in many serious diseases, can serve as 
valuable diagnostic and therapeutic targets. 
 
In the course of this thesis, the impact of various compounds on the activity of 
selected enzymes will be assayed using spectrophotometric or fluorometric 
methods. The outcomes will then be evaluated with the use of several enzyme 
kinetic evaluation methods, including a visual observation of the progress curves 
and calculation of appropriate kinetic parameters.  
 
Moreover, efforts will be made to identify and validate new activity-based probes, 
which would then serve to investigate the identity or the function of the enzyme. 
To prove that, sodium dodecyl sulfate polyacrylamide gel electrophoresis will be 
implemented. 
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4. THEORETICAL SECTION 
4.1. PROTEASES 
4.1.1. DEFINITION AND CLASSIFICATION 
 
Proteases (proteinases, peptidases) are enzymes that cleave amide bonds in a 
polypeptide chain by hydrolysis (Siklos et al. 2015). That means a water molecule 
breaks down the bond and that is why they are classified among hydrolases. 
Proteases play a crucial role in all living organisms. By shedding, they regulate 
various biological processes. Besides a destructive action, as in simple digestion, 
they can also have an activating or deactivating function (Berg et al. 2015). Good 
examples are the blood-clotting cascade, the complement system, DNA 
processing or the regulation of hormones (Copeland 2005). 
 
There are more possible ways of how to classify enzymes. According to where in 
the polypeptide chain the cleavage takes place, peptidases can be classified as 
exopeptidases or endopeptidases. Exopeptidases truncate the terminal amino 
acid, dipeptide or tripeptide either from the N- or C- terminus of the protein chain. 
These are then referred to as aminopeptidases and carboxypeptidases, 
respectively. On the contrary, peptidases cleaving inside the polypeptide chain 
are called endopeptidases (Barrett et al. 2013). 
 
Based on the active-site residue of the catalytic triad, proteases are divided into 
cysteine, serine, threonine, aspartic, asparagine, glutamic and metallopeptidases 
(Barrett et al. 2013). These groups are then divided into clans, according to the 
similarities in their spatial structure, showing the evidence of sharing the 
evolutionary origin, or families sharing the similarity in the amino acid sequence. 
The MEROPS database thoroughly sorts similar peptidases into clans, 
characterized with two letters. The first letter represents the catalytic type (e.g. C 
= cysteine protease) and the second letter defines the clan. Families are 
characterized with the same first letter, followed by a number. All enzymes of this 
thesis belong to the CA clan and C1 family, of which papain is the major 
representative (Rawlings et al. 2017).  
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4.2. CYSTEINE PROTEASES 
 
According to the MEROPS protease classification system, cysteine cathepsins 
together with rhodesain belong to the C1 family of the clan CA (Rawlings et al. 
2017). All members of this group share a high degree of homology with papain, 
found in Carica papaya (Kamphuis et al. 1984), which is the representative of this 
group. All papain-like cathepsins are composed of two domains and display a V-
shaped configuration. Besides 11 papain-like cathepsins B, C, F, H, K, L, O, S, 
V, W and X (Rossi et al. 2004), there are also four non-cysteine cathepsins 
encoded in the human genome, i.e., cathepsins A, D, G and E (Loser and 
Pietzsch 2015). Cathepsins were first observed in lysosomes and were 
considered as intracellular enzymes, responsible for non-specific, mass 
proteolysis. Nowadays, it is known that they can be extracellular or intracellular, 
and catalyze highly specialized enzymatic reactions. However, their extra-
lysosomal activity is often associated with pathological processes (Kramer et al. 
2017). Some cathepsins are ubiquituously expressed (e.g. cathepsin B and L), 
whereas others show a more tissue-specific distribution. For example cathepsin 
K is vastly expressed in osteoclasts (Saftig et al. 2000) and cathepsin S in 
immune cells (Vidak et al. 2019). 
 
4.2.1. SUBSTRATE SPECIFICITY 
 
The active site of an enzyme has two functions. At first, it needs to bind the 
substrate and then to catalyze the enzymatic reaction (Ledvina et al. 2009). The 
active site of papain-like cysteine proteases contains a set of three coordinated 
amino acids, the so-called catalytic triad, which consists of cysteine, histidine and 
asparagine (Verma et al. 2016). However, the substrate specificity is not given 
just by the amino acids of the active site, but also by the specificity subsites close 
by. The specificity subsites (S) are pockets, which can perfectly accommodate 
the amino acid residues of the substrate thanks to the matching polarity, size or 
charge (Berger and Schechter 1970). They are numbered with respect to the 
distance from the active site in the polypeptide chain, primed to the site of the    
C-terminus and non-primed to the site of the N-terminus of the substrate. Amino 
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acid residues (P) of the substrate are numbered according to the corresponding 
subsites (Berger and Schechter 1970). The scissile bond is located between P1 
and P1’ of the substrate. The nomenclature is shown in Figure 1. The amount of 




Figure 1. The nomenclature of specificity subsites and amino acid residues of 
the substrate according to Schechter and Berger. 
S – specificity subsite; P – amino acid of the substrate 
 
 
4.2.2. CATALYTIC MECHANISM 
 
As aforementioned, the catalytic triad of cysteine proteases consists of cysteine, 
histidine and asparagine. According to Lecaille et al. (2002), cysteine (present on 
the right domain) and histidine (located on the left domain) form an ion pair, which 
is stabilized by asparagine via a hydrogen bond. Histidine acts as a proton 
acceptor and enhances the nucleophilicity of the cysteine residue. The 
deprotonated cysteine residue then attacks the carbonyl carbon of the scissile 
bond of the substrate, forming a tetrahedral intermediate, yet reversible. A 
covalent bond is formed upon the release of the C-terminal portion of the 
substrate. The enzyme is then regenerated, when a water molecule hydrolyzes 
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the thioester, liberating the N-terminal portion, via a second tetrahedral 
intermediate. The corresponding mechanism is depicted in Scheme 1. 
 
 
Scheme 1. Mechanism of action of cysteine proteases.  
Adapted from Lecaille et al. (2002). 
 
4.2.3. ENDOGENOUS REGULATION 
 
Cathepsins are vital for all living organisms, however, if their regulation is not 
under control, they can cause damage to our own tissues. These enzymes play 
a crucial role in several diseases, such as cancer, neurodegenerative diseases 
(Nixon et al. 2000), muscular dystrophy (Kar and Pearson 1978), osteoporosis, 
rheumathoid arthritis (Vizovisek et al. 2019), and many more. They can also be 
the cause of therapeutic resistance (Shree et al. 2011). 
 
The activity of enzymes in the organism is regulated by various mechanisms. The 
first one is the regulation of gene expression, which means the interpretation of 
the information encoded in the genome. Post-translational modifications include 
glycosylation, S-S bridging, metal binding or proteolysis. The enzyme is usually 
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synthesized as a pre-proenzyme, which then needs to be altered to turn into a 
proenzyme, or in other words, the zymogen – an inactive form which requires to 
be shed to be functional. The shedding can either be catalyzed by other 
proteases or the zymogen is autocatalytically cleaved by the enzyme itself 
(López-Otín and Bond 2008). The pro-sequences not only serve as inhibitors, 
they can also help folding the tertiary structure of protein, stability in different pH 
than is optimal, and directing of a peptidase into the right place (Khan 1993).  
 
The microenvironment of the enzyme plays a huge role. Lysosomal cathepsins 
require a low pH for its functioning and even stability. In a neutral environment, 
they would lose their activity through irreversible denaturation (Turk et al. (1995) 
and Turk et al. (2012)). Cysteine peptidases are also sensitive to oxidation of the 
cysteine in the active site. Therefore, they require reductive environment, which 
in cells, is accomplished by the glutathione (Giles et al. 2003), whereas in our 
experiments a reductive agent, dithithreitol (DTT) is used. 
 
The activity of the activated enzyme can also be blocked by endogenous 
inhibitors. For the inhibition of cysteine cathepsins, there is a cystatin family, 
which is divided into subfamilies of stefins, kininogens and cystatins (Turk et al. 
1986). Dysregulation of these inhibitors leads to a progression of a disease 
pathology. For example, reduced cystatin levels have been shown in late stage 
tumors, and on the contrary, patients with increased levels of cystatin C are at 
higher risk of developing cardiovascular diseases and a chronic kidney disease 
(Taglieri et al. 2009). All known endogenous inhibitors of human proteases are 
proteins or peptides. Another possible way of enzyme regulation is targeting to 
specific compartments such as lysosomes or mitochondria (Ahn and Yun 2010).  
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4.2.4. CATHEPSIN B 
 
Cathepsin B is a lysosomal enzyme, which can act as both an endopeptidase 
and exopeptidase (dipeptidylpeptidase), depending on the surrounding pH. (Illy 
et al. 1997). This feature is accomplished by the presence of an occluding loop 
in the structure, that enhances the accessibility of the substrate into the active 
site (Illy et al. 1997). Elevated levels of this cathepsin have been observed in 
various types of cancer, such as gastric (Ebert et al. 2005), esophageal (Hughes 
et al. 1998), breast (Kos et al. 2000) or prostatic cancer (Fernandez et al. 2001). 
Cathepsin B has been shown to contribute to apoptosis as an antagonist and its 
absence results in increased apoptosis (Gocheva et al. 2006). A lack of cathepsin 
B also decreases angiogenesis and impairs tumor invasion (Gocheva et al. 
2006). This cysteine protease is released in a high abundance during obesity by 
white adipose tissue in hypertrophied adipocytes. The activity of autophagy 
systems is increased and the levels of proinflammatory markers are modulated, 
leading to even higher macrophage infiltration. Hence, cathepsin B is found to 
contribute to metabolic syndrome (Araujo et al. 2018). The functional importance 
of cathepsin B is complicated by the fact that it regulates the function of related 
proteases. Inhibition of cathepsin B causes, for example, a deficiency of 
cathepsin L, which results in stimulation of cell proliferation in neoplasia 
(Gopinathan et al. 2012).  
  
4.2.5. CATHEPSIN K 
 
Cathepsin K is the most potent mammalian collagenase and plays a specialized 
role in bone resorption under both normal and pathological conditions (Barry and 
Platt 2012). This cathepsin is highly expressed in osteoclasts (Bromme et al. 
1996) and secreted into the bone lacunae, the extracellular matrix, where it 
digests the peptidic portion of bone tissue, which is mainly made of type I collagen 
(Drake et al. 1996). Cathepsin K also has a strong elastinolytic activity (Bromme 
et al. 1996) and its overexpression is present in osteoarthritis, lung fibrosis, 
atherosclerosis and breast cancer (Littlewood-Evans et al. 1997) as well as in 
cervical and lung cancer (Chen and Platt 2011). 
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4.2.6. CATHEPSIN L 
 
Under physiological conditions, cathepsin L is a ubiquitous, endolysosomal 
protease taking care of degradation of intracellular or exocyted proteins. This 
cathepsin is, for example, physiologically responsible for a follicular rupture 
during ovulation (Robker et al. 2000). However, in cancer, its secretion is also 
extended into the extracellular matrix. There, it hydrolyzes the interstitium and 
basal membranes, allowing the tumor to invade either locally or to metastasize 
into distant areas. The upregulation of cathepsin L often correlates with the tumor 
grade (Skrzypczak et al. (2012), Lah et al. (1997)) and can even be the key factor 
driving the neoplastic progression (Herszenyi et al. 1999). Additionally, its 
overexpression is present in several other human diseases, including diabetes 
(Huang et al. 2003), abdominal aortal aneurysm (Lv et al. 2013) or liver fibrosis 
(Manchanda et al. 2017).  
 
4.2.7. CATHEPSIN S 
 
Cathepsin S is an endopeptidase, which differs from many family members with 
the higher ability to remain active also at the neutral pH, thus has an increased 
potential to take part in the extracellular proteolysis (Wilkinson et al. 2015). The 
tissue expression of this cathepsin is mainly restricted to spleen and lymph, 
where it has been shown to be the key protease responsible for processing and 
degradation of autoantigens on antigen-presenting cells, such as T cells, B cells, 
macrophages or dendritic cells (Smith and Simons 2002). Therefore, its aberrant 
activity results in the induction of autoimmune diseases (Stoeckle et al. 2012) like 
bronchial asthma, rheumatoid arthritis, psoriasis, multiple sclerosis, myasthenia 
gravis and autoimmune diabetes (Hsing et al. 2010). Cathepsin S acts as a potent 
elastase in cardiovascular diseases such as atherosclerosis or abdominal aortic 
aneurysm (Jadhav et al. 2014). Moreover, increased levels of this protease are 
present in chronic renal disease (Sena et al. 2017). Cathepsin S is also a key 
contributor to nociceptive hypersensitivity in neuropathic pain (Clark et al. 2010). 





Rhodesain is a cathepsin L-like enzyme, which in contrast to the previous 
enzymes, is never present in the human body naturally. Rhodesain, synthesized 
by Trypanosoma brucei rhodesiense (T. b. rhodesiense), is essential for survival 
of this parasite and is also required to cross the blood-brain barrier of the human 
host (Lonsdale-Eccles and Grab 2002). T. b. rhodesiense is a single-cell parasite 
which causes African trypanosomiasis, also known as sleeping sickness, 
transmitted by the tsetse fly mainly in sub-Saharan Africa (Brun et al. 2010). 
When entering the host, the first, hemolymphatic stage of the disease is 
manifested by attacks of fever, headaches, joint pains and itching. The real 
danger begins with the second stage of the disease, when the parasite reaches 
the central nervous system. The latter stage includes a disruption of the sleep 
cycle, confusion, tremor, hemiparesis, etc. According to chemical evidence of 
Steverding et al. (2012), even though rhodesain is essential for the survival of 
T. b. rhodesiense, its activity must be inhibited completely to kill the parasite, 
otherwise it just prolongs the life of the patient. 
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4.3. ENZYME INHIBITION 
 
When the binding of a molecule causes a decrease in the enzyme activity or even 
stops the enzymatic reaction without the protein destruction, the phenomenon is 
called enzyme inhibition (Ledvina et al. 2009). This naturally occurs during cell 
processes to maintain homeostasis, or abnormally by undesired products of 
metabolism, toxins or pharmaceutical drugs. Inhibition can be distinguished as 
reversible or irreversible, based on the strength of the bond between the enzyme 
and the inhibitor. 
 
4.3.1. IRREVERSIBLE INHIBITION  
 
Irreversible inhibitors tightly bind to their target enzyme, resulting in that the 
inhibitor cannot dissociate from the enzyme easily (Berg et al. 2015). In general, 
they modify the enzyme covalently, however, in certain cases, non-covalently 
bound inhibitors can also remain permanently connected to the enzyme. 
Irreversible inhibitors usually contain a reactive functional group, e.g., Michael 
acceptors, aldehydes or nitrogen mustards, which reacts with nucleophilic active-
site amino acid residues of the enzyme (Bhatt 2001). The inhibition occurs in a 
time-dependent manner. In contrary to reversible inhibition, the reaction leads to 
a completion rather than an equilibrium. Irreversible inhibitors interact with their 
target in a two-step mechanism, consisting of the formation of a non-covalent 
complex, followed by the establishment of the covalent bond between enzyme 
and inhibitor (Singh et al. 2011). A very known example of the irreversible 
inhibition is acetylsalicylic acid acetylating the active-site serine of 
cyclooxygenase. To regain the activity, new cyclooxygenase must be 





Figure 2. Scheme of irreversible inhibition. 
 
4.3.2. REVERSIBLE INHIBITION  
 
Reversible inhibitors form an unstable complex with the enzyme, mostly using 
non-covalent interactions such as hydrogen bonds, hydrophobic interactions or 
ionic bonds. Nevertheless, a reversible covalency can also be achieved with, for 
example, highly electron-deficient olefins (Senkane et al. 2019). 
 
Some inhibitors can bind to the active site of the enzyme, preventing binding of 
the substrate, because they cannot occupy the enzyme at the same time (Bhatt 
2001). Hence, they compete for the enzyme’s active site and that is why this type 
of inhibition is called the competitive inhibition (Figure 3a). 
 
In other cases, the inhibitor binds to the so-called allosteric site of the protein. An 
allosteric site is simply any other place than the active site, where the binding of 
the inhibitor causes a change in arrangement, which is no longer optimal to 
catalyze the enzymatic reaction (Srinivasan et al. 2014). This type of inhibition 
does not prevent the substrate from binding the enzyme, but decreases the 
efficiency of the enzyme (Ledvina et al. 2009). Since the allosteric site differs from 
the active site, the inhibitor binds to the enzyme alone or enzyme-substrate 
complex with the same affinity (Delaune and Alsayouri 2019). This type of 
inhibition is called the non-competitive inhibition (Figure 3b). 
 
In the uncompetitive inhibition, the inhibitor exclusively binds to the site that 
becomes available only after a formation of the enzyme-substrate complex, which 
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causes a conformational change in the enzyme (McPherson and Pincus 2017), 
and precludes the product formation. This typically occurs when more substrates 
take part in the enzymatic reaction at the same time (Roskoski 2008) (Figure 3c). 
 






Figure 3. Schemes of reversible inhibition. 
a) competitive; b) non-competitive; c) uncompetitive inhibition 
E – enzyme; P – product; I – inhibitor  
 
4.3.3. SLOW-BINDING INHIBITION 
Slow-binding inhibitors can bind to the enzyme covalently or non-covalently, but 
always in a time-dependent manner (Silverman 2004). The enzymatic reaction is 
characterized by an initial burst, followed by a lower steady-state velocity. In 
contrary to the regular irreversible inhibition, the reaction leads to an equilibrium 
between the free enzyme and the enzyme-inhibitor complex instead of a 
completion. Unlike in classical reversible inhibition, where the equilibrium is 
established in milliseconds, the equilibrium in the slow-binding inhibition is 
established rather slowly, on a time scale of seconds to minutes (Morrison and 
Walsh 1988). Two possible mechanisms of the slow-binding inhibition have been 
proposed. The first mechanism suggests a direct, but slow binding of the inhibitor 
resulting in an inactivation. The second mechanism involves a rapid non-covalent 





isomerization into the inactive enzyme-inhibitor complex (Sculley et al. 1996). 









Figure 4. Two possible mechanisms of the slow-binding inhibition. 
a) direct slow-binding inhibition; b) slow-binding inhibition involving the collision 
complex 
 
4.4. ACTIVITY-BASED PROTEOMICS 
 
Activity-based protein profiling (ABPP) or activity-based proteomics is a method 
utilizing small synthetic fluorescently or radioactively marked molecules that are 
designed to covalently react with the active site of the enzyme. Such molecules 
are called activity-based probes (ABPs). They selectively tag only active 
enzymes, whereas those in their inactive forms remain unlabeled. This enables 
to differentiate between the enzyme abundance and its elevated activity, which 
is regulated by a series of post-translational modifications (Serim et al. 2012). 
Protease ABPs are composed of three parts. A reactive group (warhead) 
covalently binds to the target enzyme. Then, there is a linker, often consisting of 
a peptide chain similar to the substrate, which helps to induce selectivity. Last but 
not least, the ABP also contains a fluorescent or radioactive reporter, allowing for 
a direct detection of the active enzyme (Sadaghiani et al. 2007). This method has 
emerged as a powerful proteomic strategy to identify the enzyme function in 
native material (Cravatt et al. 2008). In the course of this thesis, labeling of the 




4.5. SDS-PAGE  
 
SDS-PAGE is an electrophoresis in polyacrylamide gel in the presence of sodium 
dodecyl sulfate. This analytical method serves for the separation of proteins 
according to their molecular weight under the influence of an applied electrical 
field (Weber and Osborn 1969). SDS is an anionic detergent, used to mask the 
intrinsic net charge of proteins and to destroy their tertiary structure, resulting in 
the linear molecule with the negative charge, proportional to the length of the 
polypeptide chain. Whilst moving through the gel by application of an electric 
current, larger molecules are retained by the polyacrylamide gel, causing smaller 
molecules to migrate faster, thus further. The molecular mass can be estimated 
by a calculation with the relative migration distance or by comparison with a 
commercially available protein standard. When using a higher acrylamide 
concentration, the smaller mesh size gel is produced, which allows for 
a separation of smaller proteins.   
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5. EXPERIMENTAL SECTION  
5.1. MATERIAL 
 
Rhodesain was expressed and purified by Dr. Patrick Johe at the University of 
Mainz, Germany in the group of Prof. Dr. Tanja Schirmeister as described in 
(Caffrey et al. 2001). Cathepsin K, L and S were acquired from Enzo Life 
Sciences (Lörrach, Germany). Human cathepsin B and substrates (Z-Arg-Arg-
pNA, Z-Phe-Arg-pNA, Z-Phe-Val-Arg-pNA, Z-Leu-Arg-AMC and Z-Phe-Arg-
AMC) were purchased from Calbiochem (Merck, Darmstadt, Germany). EDTA 
disodium salt dihydrate was obtained from AppliChem GmbH (Darmstadt, 
Germany). Citric acid monohydrate, Coomassie Brilliant Blue R 250, di-sodium 
hydrogen phosphate dihydrate, Roti®-Nanoquant, sodium dihydrogen phosphate 
dihydrate, SDS, TEMED and Tris were acquired from Carl Roth GmbH + Co. KG 
(Karlsruhe, Germany). Acrylamide was bought from Merck (Darmstadt, 
Germany). Sodium chloride and methanol were obtained from Fisher Scientific 
U.K. Limited (Loughborough, United Kingdom). Brij 35 P was purchased from 
Fluka Chemie GmbH (Buchs, Switzerland). Tri-sodium citrate dihydrate and 
dimethylsulfoxide were purchased from Acros Organics (Geel, Belgium). Glycine 
was bought from Promega Corporation (Madison, USA). Acetic acid was 
obtained from VWR International S.A.S (Fontenay-sous-Bois, France). 2-




Thermomixer Comfort, mechanical pipettes by Eppendorf (Hamburg, Germany) 
were used. Pipette tips sold by Sarstedt AG & Co. KG (Nümbrecht, Germany) 
were used. The chamber for SDS-PAGE, glass plates, buffer dam and combs 
were purchased from Bio-Rad (Hercules, USA). As a vortex mixer, Vortex-Genie 
from Scientific Industries was used. Disposable cuvettes were purchased from 
Brand GmbH + Co KG (Wertheim, Germany). Stirring spatula were obtained from 
Carl Roth GmbH + Co. KG (Karlsruhe, Germany). The spectrophotometer Cary 
50 Bio by Varian (Australia) was used. For fluorometric measurements, the 
FLUOstar OPTIMA was acquired from BMG LABTECH GmbH (Ortenburg, 
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Germany). All kinetic evaluations were performed in GraFit 5.0, a data analysis 
software for Windows. Chemical structures were drawn in ChemDraw. 
 
5.3. METHODS  
5.3.1. DETECTION 
 
The inhibitory potential of an enzyme inhibitor is characterized by detecting the 
decrease in metabolite creation by the enzyme in the presence of inhibitor. That 
becomes measurable when using chromogenic or fluorogenic substrates. In the 
course of this thesis, para-nitroaniline (pNA) was used as the chromogenic 
substrate. During the enzymatic reaction, para-nitroaniline is cleaved from the 
substrate by the enzyme, causing yellow coloring of the solution, which is 
measured by a UV-VIS spectrophotometer at 405 nm and expressed as the 
absorption per time. As a fluorometric read-out modality of the substrate 
consumption, 7-amino-4-methylcoumarin (AMC) was used. The emission of light 
(fluorescence) by released 7-amino-4-methylcoumarin is measured after 
excitation by the light with a wavelength of 360 nm and the emission wavelength 
of 440 nm on the plate reader. Examples are depicted in Scheme 2. 
 
 
a) Z-Phe-Arg-pNA  Z-Phe-Arg-OH   + 
 
 
b) Z-Leu-Arg-AMC  Z-Leu-Arg-OH  +  
 
Scheme 2. Mechanism of detection. 
Hydrolysis of a) chromogenic substrate by rhodesain and b) fluorogenic substrate 










5.3.2. KINETIC EVALUATIONS 
 
The inhibitory activity of substances towards an enzyme can be quantified in 
terms of IC50, Ki or kinact/Ki values. The IC50 value is defined as the concentration 
of the inhibitor at which the reaction rate is at half of the reaction rate without 
inhibitor (Georgakis et al. 2020). This constant can be calculated with the use of 
equation a in Figure 5. According to Sisay et al. (2009), in case of possible 
interactions in the enzymatic reaction, a stoichiometric parameter has to be 
applied, resulting in the so-called three-parameter equation (Figure 5b). The 
potentially time-dependent IC50 is a suitable way to quantify the inhibitory activity 
of reversible inhibitors, but may cause problems when dealing with irreversible 
inhibitors (Krippendorff et al. 2009). The inhibitory constant (Ki), in contrast to 
IC50, is independent of the substrate concentration and the results obtained under 
different assay conditions are directly comparable. The Ki value can be calculated 
with the Cheng-Prusoff equation (Figure 5c), using IC50, substrate concentration 
[S] and Michaelis-Menten value (KM) (Cheng and Prusoff 1973).  
 
Since covalent, thus irreversible inhibitors interact with their target in the 
aforementioned two-step mechanism, two parameters are important for their 
description. The affinity of the initial non-covalent binding is characterized by Ki 
and the formation of the covalent bond by the inactivation rate constant (kinact) 
(Schmitz 2016). Together, they make up the second-order rate constant of 
inactivation (kinact/Ki), which can be obtained by non-linear regression of first-
order rate constant (kobs) and inhibitor concentration [I] data pairs, using the 
equation d in Figure 5 (Tonge 2019). According to Copeland (2005), the first-
order rate constant (kobs), also known as observed inhibition rate constant, 
describes the conversion of initial velocity of the biochemical reaction to its 
steady-state velocity (Figure 5e). When each kobs is plotted versus its 
corresponding inhibitor concentration, kinact can be observed as the maximum 
asymptote (Drawz et al. 2010). The concentration of the inhibitor at which the rate 
of inactivation is equal to half of kinact is IC50. Ki can be then easily calculated with 
the formula c in Figure 5. 
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Since the inhibitors with slow-binding behavior inhibit the target enzyme in a time-
dependent manner, it is usually described by the inhibition constant (Ki) and, 
moreover, the association (kon) and the dissociation constant (koff) (Frizler 2012). 
At first, steady-state reaction rates (vs) and the first-order rate constants (kobs) 
have to be calculated with the slow-binding equation (Figure 5f) (Copeland 
2005). When plotting the steady-state velocities against inhibitor concentrations 
and analyzing by non-linear regression (Figure 5a), the IC50 value can be 
acquired. Correction of IC50 value by the use of the Cheng-Prusoff equation 
(Figure 5c) results in the inhibitory constant (Ki). When kobs is plotted versus 
inhibitor concentration [I], the apparent association constant (kon’) can be 
obtained with the equation g in Figure 5. The apparent association rate constant 
(kon’) is then corrected with the factor (1+[S]/KM), according to equation h in 
Figure 5, resulting in the true association constant (kon) (Gütschow and Neumann 
1998). The true association constant is then applied in the equation i in Figure 5 







































g) 𝑘obs = 𝑘off + 𝑘on′ × [I] 




i) 𝑘off = 𝐾i × 𝑘on 
 
Figure 5. General equations. 
a) IC50 calculation (two-parameter); b) three-parameter equation; c) Cheng-
Prusoff equation; d) Non-linear regression for kinact; e) Exponential product 
formation and kobs evaluation; f) Slow-binding equation; g) determination of kon’; 
h) determination of kon; i) koff calculation. 
[I] – inhibitor concentration; [P] – product concentration; [S] – substrate 
concentration; d – offset; IC50 – half maximal inhibitory concentration; Ki – 
inhibitory constant; kinact – inactivation rate constant; KM – Michaelis-Menten 
constant; koff – dissociation constant; kon – association constant; kon’ – apparent 
association constant; t – time; v0 – reaction rate in the absence inhibitor; vi – initial 
velocity of product formation; vs – steady-state reaction rate in the presence of 
inhibitor; x – parameter for a reaction stoichiometry. 
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5.3.3. MICHAELIS-MENTEN CONSTANT 
 
The affinity of an enzyme for a certain substrate under specific assay conditions 
is described by the Michaelis-Menten constant (KM) (Ledvina et al. 2009). Its 
value is numerically equal to the concentration of the substrate at which the 
velocity of the enzyme reaction is half of the maximum (Figure 6a). The KM value 
is dependent on the assay environment, such as pH, temperature or presence of 
effectors (Meisenberg and Simmons 2011). The lower KM value means the higher 
affinity of the enzyme for the concrete substrate. 
 
Linear plotting of the Michaelis-Menten equation helps to estimate KM and Vmax 
more accurately (Inamdar 2012). Before the non-linear curve-fitting on computers 
was so available, several researchers developed linearization methods of the 
Michaelis-Menten equation. Nowadays, computer software allows for more 
accurate non-linear regression methods, however, linear plotting can be useful 
for visualization of data (Lorsch 2014). 
 
To review possible systematic errors, the Lineweaver-Burk and Hanes-Woolf 
































Figure 6. a) Michaelis-Menten; b) Hanes-Woolf; c) Lineweaver-Burk equations. 
vs – steady-state velocity (M s-1); Vmax – maximal reaction velocity (M s-1); [S] – 
substrate concentration (M); KM – Michaelis-Menten constant (M). 
 31 
 
Figure 7. Michaelis-Menten plot. 
 
The Hanes-Woolf plot, shown in Figure 8, is a graphical representation of the 
Hanes-Woolf equation (Figure 6b) of enzyme kinetics. The ratio of the substrate 
concentration and the reaction velocity is plotted against the substrate 
concentration (Inamdar 2012). This graphical representation is considered to be 
more accurate than the one of Lineweaver and Burk (Marasović et al. 2017). 
 
 




The linearization method of Lineweaver-Burk plot (Figure 9) is a commonly used 
double reciprocal plot, which means that the inverse of the reaction rate is plotted 
against the inverse of the substrate concentration. Its equation has been 
described by Hans Lineweaver and Dean Burk in 1934 (Figure 6c). The main 
drawback is that the method is prone to error, since the reciprocity increases any 
small errors in the measurement. Additionally, the data points are not evenly 
distributed. Those at higher substrate concentrations are compressed into a small 
area, whereas the data points at lower concentrations, which are in general less 
accurate, affect the slope the most (Marasović et al. 2017). 
 
Figure 9. Lineweaver-Burk plot. 
 
Rhodesain KM Value Assay: UV-Photometer 
 
Rhodesain was assayed spectrophotometrically on a Cary 50 Bio, Varian at 405 
nm and 25 °C in cuvettes. The enzyme (4 mg/mL in 10 mM sodium citrate buffer 
pH 5.0) was activated with a buffer containing 50 mM sodium acetate pH 5.5, 200 
mM NaCl, 5 mM EDTA and 2 mM DTT by diluting 1:849 and was then incubated 
at 25 °C for 30 min. A 10 mM stock solution of the chromogenic substrate Z-Phe-
Arg-pNA was prepared in DMSO. Into a cuvette containing 960 µL of the assay 
buffer (50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM EDTA, 0,005% Brij 
35), 10 increasing amounts of the substrate, 2% DMSO and 20 µL of the enzyme 
(94,1 ng/mL) were pipetted. The final substrate concentrations were 1, 2, 4, 6, 8, 
10, 20, 30, 40 and 50 µM. The measurements were followed for 10 minutes in 
triplicate.  
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5.3.4. ENZYME INHIBITION ASSAYS 
 
Rhodesain Inhibition Assay: UV-Photometer 
 
Rhodesain was assayed spectrophotometrically on a Cary 50 Bio, Varian at 
405 nm and 25 °C in cuvettes. The enzyme (4 mg/mL in 10 mM sodium citrate 
buffer pH 5.0) was activated with a buffer containing 50 mM sodium acetate pH 
5.5, 200 mM NaCl, 5 mM EDTA and 2 mM DTT by diluting 1:850 and incubating 
at 25 °C for 30 min. A 10 mM stock solution of the chromogenic substrate Z-Phe-
Arg-pNA was prepared in DMSO. The final substrate concentration was 40 µM 
(= 10.38 x KM). The assays were performed with a final concentration of rhodesain 
of 23.5 ng/mL. Stock solutions of inhibitors were prepared in DMSO. The final 
DMSO concentration in each cuvette was 2% (20 µL). Into a cuvette containing 
975 µL of the assay buffer (50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM 
EDTA, 0,005% Brij 35), 4 µL of the chromogenic substrate, DMSO and inhibitor 
solution (16 µL) were pipetted. Upon addition of rhodesain (5 µL), the 
measurement was started and followed for 60 min. Adapted from (Klein et al. 
2020) 
 
Cathepsin B Inhibition assay: UV-photometer 
 
Cathepsin B was assayed spectrophotometrically on a Cary 50 Bio, Varian at 
405 nm and 37 °C in cuvettes, according to Frizler et al. (2011). The enzyme 
(470 µg/mL in 20 mM sodium acetate buffer pH 5.0 and 1 mM EDTA) was 
activated with 100 mM sodium phosphate buffer pH 6.0 containing 100 mM NaCl, 
5 mM EDTA, 0.01% Brij 35 and 5 mM DTT by diluting 1:500 and incubating at 
37 °C for 30 min. A 100 mM stock solution of the chromogenic substrate Z-Arg-
Arg-pNA was prepared in DMSO. The final substrate concentration was 500 µM 
(= 0.45 × KM). The assays were performed with a final concentration of cathepsin 
B of 19 ng/mL. Stock solutions of inhibitors were prepared in DMSO. The final 
DMSO concentration in each cuvette was 2% (20 µL). Into a cuvette containing 
960 µL of the assay buffer (100 mM sodium phosphate buffer pH 6.0, 100 mM 
NaCl, 5 mM EDTA, 0.01% Brij 35), 5 µL of the chromogenic substrate, DMSO 
and inhibitor solution (15 µL) were pipetted. Upon addition of cathepsin B (20 µL), 
the measurement was started and followed for 60 min. 
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Cathepsin L Inhibition assay: UV-photometer 
 
Cathepsin L was assayed spectrophotometrically on a Cary 50 Bio, Varian at 
405 nm and 37 °C in cuvettes, according to Frizler et al. (2011). The enzyme 
(135 µg/mL in 20 mM malonate buffer pH 5.5, 400 mM NaCl and 1 mM EDTA) 
was activated with 100 mM sodium phosphate buffer pH 6.0 containing 100 mM 
NaCl and 5 mM EDTA, 0.01% Brij 35 and 5 mM DTT by diluting 1:100 and 
incubating at 37 °C for 30 min. A 10 mM stock solution of the chromogenic 
substrate Z-Phe-Arg-pNA was prepared in DMSO. The final substrate 
concentration was 100 µM (= 5.88 × KM). The assays were performed with a final 
concentration of cathepsin L of 54 ng/mL. Stock solutions of inhibitors were 
prepared in DMSO. The final DMSO concentration in each cuvette was 2% 
(20 µL). Into a cuvette containing of the 940 µL assay buffer (100 mM sodium 
phosphate buffer pH 6.0, 100 mM NaCl, 5 mM EDTA, 0.01% Brij 35), 10 µL of 
the chromogenic substrate, DMSO and inhibitor solution (10 µL) were pipetted. 
Upon addition of cathepsin L (40 µL), the measurement was started and followed 
for 60 min. 
 
Cathepsin K Inhibition assay: UV- photometer 
 
Cathepsin K was assayed spectrophotometrically on a Cary 50 Bio, Varian at 
405 nm and 37 °C in cuvettes, according to Frizler et al. (2011). The enzyme 
(23 µg/mL in 50 mM sodium acetate buffer pH 5.5, 50 mM NaCl, 0.5 mM EDTA, 
5 mM DTT) was activated with 100 mM sodium citrate buffer pH 5.0 containing 
100 mM NaCl, 1 mM EDTA, 0.01% CHAPS and 5 mM DTT by diluting 1:100 and 
incubating at 37 °C for 30 min. A 10 mM stock solution of the chromogenic 
substrate Z-Phe-Arg-pNA was prepared in DMSO. The final substrate 
concentration was 100 µM (= 0.85 × KM). The assays were performed with a final 
concentration of cathepsin K of 54 ng/mL. Stock solutions of inhibitors were 
prepared in DMSO. The final DMSO concentration in each cuvette was 2% 
(20 µL). Into a cuvette containing of the 940 µL assay buffer (100 mM sodium 
phosphate buffer pH 6.0, 100 mM NaCl, 5 mM EDTA, 0.01% Brij 35), 10 µL of 
the chromogenic substrate, DMSO and inhibitor solution (10 µL) were pipetted. 
Upon addition of cathepsin K (40 µL), the measurement was started and followed 
for 60 min. 
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Cathepsin K Inhibition assay: plate reader 
 
Cathepsin K was assayed fluorometrically on a FLUOSTAR Optima plate reader 
at 25 °C with an excitation wavelength of 360 nm and an emission wavelength of 
440 nm on a 96 well plate, according to Frizler (2012). The enzyme (23 µg/mL in 
50 mM sodium acetate pH 5.5, 50 mM NaCl, 0.5 mM EDTA, 5 mM DTT) was 
activated with 100 mM sodium citrate buffer pH 5.0 containing 100 mM NaCl, 
1 mM EDTA 0.01% CHAPS and 5 mM DTT by diluting 1:100 and incubating at 
37 °C for 30 min. A 10 mM stock solution of the fluorogenic substrate Z-Leu-Arg-
AMC was prepared in DMSO. The final substrate concentration was 40 µM           
(= 13.33 × KM). The assays were performed with a final concentration of cathepsin 
K of 4.61 ng/mL. Stock solutions of inhibitors were prepared in DMSO. The final 
DMSO concentration in each well was 2% (4 µL). Into a well containing 192 µL 
of the assay buffer (100 mM sodium citrate buffer pH 5.0, 100 mM NaCl, 1 mM 
EDTA and 0.01% CHAPS), 0.8 µL of the fluorogenic substrate, DMSO and 
inhibitor solution (3.2 µL) were pipetted. Upon addition of cathepsin K (4 µL), the 
measurement was started and followed for 60 min. 
 
Cathepsin S Inhibition assay: UV- photometer 
 
Cathepsin S was assayed spectrophotometrically on a Cary 50 Bio, Varian at 
405 nm and 37 °C in cuvettes, according to Frizler et al. (2011). The enzyme 
(70 µg/mL in 199 mM MES buffer pH 6.5, 1 mM EDTA, 50 mM L-cysteine, 10 mM 
DTT, 0.5% Triton X-100 and 30% glycerol) was activated with 100 mM sodium 
phosphate buffer pH 6.0 containing 50 mM NaCl, 2 mM EDTA, 0.01% Triton X-
100 and 5 mM DTT by diluting 1:100 and incubating at 37 °C for 60 min. A 10 mM 
stock solution of the chromogenic substrate Z-Phe-Val-Arg-pNA was prepared in 
DMSO. The final substrate concentration was 70 µM (= 0.58 × KM). The assays 
were performed with a final concentration of cathepsin S of 28 ng/mL. Stock 
solutions of inhibitors were prepared in DMSO. The final DMSO concentration in 
each cuvette was 2% (20 µL). Into a cuvette containing 940 µL of the assay buffer 
(100 mM sodium phosphate buffer pH 6.0, 100 mM NaCl, 5 mM EDTA, 0.01% 
Brij 35), 7 µL of the chromogenic substrate, DMSO and inhibitor solution (13 µL) 
were pipetted. Upon addition of cathepsin S (40 µL), the measurement was 
started and followed for 60 min. 
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Cathepsin S Inhibition assay: plate reader 
 
Cathepsin S was assayed fluorometrically on a FLUOSTAR Optima plate reader 
at 25 °C with an excitation wavelength of 360 nm and an emission wavelength of 
440 nm on a 96 well plate, according to Mertens et al. (2014). The enzyme 
(70 µg/mL in 199 mM MES buffer pH 6.5, 1 mM EDTA, 50 mM L-cysteine, 10 mM 
DTT, 0.5% Triton X-100 and 30% glycerol) was activated with 100 mM sodium 
phosphate buffer pH 6.0 containing 100 mM NaCl, 5 mM EDTA, 0.01% Brij 35 
and 5 mM DTT by diluting 1:100 and incubating at 37 °C for 60 min. A 10 mM 
stock solution of the fluorogenic substrate Z-Phe-Arg-AMC was prepared in 
DMSO. The final substrate concentration was 40 µM (= 0.74 × KM). The assays 
were performed with a final concentration of cathepsin S of 42 ng/mL. Stock 
solutions of inhibitors were prepared in DMSO. The final DMSO concentration in 
each well was 2% (4 µL). Into a well containing 184 µL of the assay buffer 
(100 mM sodium phosphate buffer pH 6.0, 100 mM NaCl, 1 mM EDTA, 0.01% 
Brij 35), 0.8 µL of the fluorogenic substrate, DMSO and inhibitor solution (3.2 µL) 
were pipetted. Upon addition of cathepsin S (12 µL), the measurement was 




The gel is composed of two different layers, thus was cast in two steps. At first, a 
12% running gel was prepared in a falcon using components as indicated below 
(Table 1) and mixed by turning upside down and back couple times. Ammonium 
persulfate (APS) serves as the radical initiator. After addition of 
tetramethylethylenediamine (TEMED), which serves as the catalyst, the solution 
had to be poured between the glass plates immediately. The gel solution was 
overlaid with isopropyl alcohol to prevent the meniscus and to protect the gel 
against the radical scavenger oxygen. The acrylamide had been left for 
polymerizing for approximately an hour. The rest of the gel solution in the falcon 
was used for estimating the polymerization between the glass plates. When the 
reaction was finished, the stacking gel solution was prepared under the same 
conditions and was poured in after discarding the isopropanol. A comb was 
immediately inserted and the gel was left polymerizing for, again, approximately 
an hour. 
 
Table 1. Composition of running and stacking gels used in SDS-PAGE. 
RUNNING GEL (12%) STACKING GEL (5%) 
12 mL 30% Acrylamide 1.67 mL 30% Acrylamide 
11.25 mL Tris-buffer (pH 8.8, 
1 mM) 
1.25 mL Tris-buffer (pH 6.8, 
1 mM) 
6.5 mL H2O 7 mL H2O 
150 µL 20% SDS 50 µL 20% SDS 
150 µL 10% APS 50 µL 10% APS 
Mix Mix 




The running buffer consists of 200 mM glycine, 25 mM Tris HCl (pH 6.8), 0.1% 
SDS and distilled water. 
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ABP-Based Labeling Experiment with DTT 
 
An amount of 4 µg of rhodesain (1 µL of the stock solution) was activated with 
29 µL of the activation buffer (50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM 
EDTA, 2 mM DTT) and incubated for 30 minutes at 25 °C. Decreasing amounts 
of the enzyme (500, 250, 200, 150, 100, 50 ng) were treated with 20 µM of the 
ABP, 2% of DMSO and activation buffer with total volume of 40 µL in micro-
reaction vessels. One control containing 500 ng of the enzyme without the 
inhibitor was prepared. Solutions were incubated at 25 °C for 1 hour. After that, 
8 µL of purple gel loading dye was added into each vessel, which were then 
subsequently denatured at 95 °C for 5 minutes. A molecular weight marker was 
loaded into the first gel well. Samples were carefully pipetted into their dedicated 
wells. Thereafter, a voltage of 120 V was applied until the loading dye reached 
approximately 1.5 cm from the end. The gel was then analyzed using a common 
gel documentation device, ChemiDoc by Bio-Rad. The assay conditions were 
adapted from Frizler et al. (2013). 
  
ABP-Based Labeling Experiment without DTT 
 
Decreasing amounts of rhodesain (500, 250, 200, 150, 100, 50 ng) were treated 
with 20 µM of the ABP and 2 µL of DMSO in the assay buffer (50 mM sodium 
acetate pH 5.5, 200 mM NaCl, 5 mM EDTA, 0,005% Brij 35). The control sample 
contained 500 ng of rhodesain, the assay buffer and 2 µL of DMSO. The total 
volume in each micro-reaction vessel was 12 µL. Solutions were incubated at 
25 °C for 1 hour. After that, 2.4 µL of the purple gel loading dye was pipetted into 
each vessel and the solutions were subsequently denatured at 75 °C for 10 
minutes. A molecular weight marker was loaded into the first gel well. Samples 
were carefully pipetted into their dedicated wells. Thereafter, a voltage of 120 V 
was applied until the loading dye reached approximately 1.5 cm from the end. 
The gel was then analyzed using a common gel documentation device, 





Competition Experiment with DTT 
 
An amount of 4 µg of rhodesain (1 µL of the stock solution) was activated with 
29 µL of the activation buffer (50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM 
EDTA, 2 mM DTT) and incubated at 25 °C for 30 minutes. Two dilutions of each, 
E-64 and ABP were prepared. Samples were prepared according to Table 2. 
A molecular weight marker was loaded into the first gel well. Samples were 
carefully pipetted into their dedicated wells. Thereafter, a voltage of 120 V was 
applied until the loading dye reached approximately 1.5 cm from the end. The gel 
was then analyzed using ChemiDoc by Bio-Rad. The assay conditions were 
adapted from Frizler et al. (2013). 
 
Table 2. Pipetting scheme for the competition experiment with DTT.  
 Neg. control E-64 E-64/ABP ABP 
Assay buffer (µL) 35.45 35.45 34.65 35.45 
Enzyme 








DMSO (µL) 0.8 - - - 
E-641 - 0.8 - - 
E-642 - - 0.8 - 
incubation at 25 °C for 10 min 
ABP1 - - - 0.8 
ABP2 - - 0.8 - 
Incubation at 25 °C for 40 min 
Loading Dye (µL) 8 8 8 8 
Denaturation at 95 °C for 5 min 
1Dilution 1000 µM of an inhibitor in DMSO. 
2Dilution 1000 µM of an inhibitor in a solution of DMSO and assay buffer 1:1. 
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Competition Experiment without DTT 
 
Two dilutions of each, E-64 and the ABP were prepared. Samples were prepared 
according to Table 3. A molecular weight marker was loaded into the first gel 
well. Samples were carefully pipetted into their dedicated wells. Thereafter, a 
voltage of 120 V was applied until the loading dye reached approximately 1.5 cm 
from the end. The gel was then analyzed using ChemiDoc by Bio-Rad. The assay 
conditions were adapted from Mertens et al. (2014) 
 
Table 3. Pipetting scheme for the competition experiment without DTT.  
 Neg. control E-64 E-64/ABP ABP 
Assay buffer (µL) 8.75 8.75 8.75 8.75 
Enzyme 
500 ng/    
1.25 µL 
500 ng/   
1.25 µL 
500 ng/    
1.25 µL 
500 ng/   
1.25 µL 
DMSO (µL) 2 - - - 
E-641 - 2 - - 
E-642 - - 1 - 
incubation at 25 °C for 10 min 
ABP1 - - - 2 
ABP2 - - 1 - 
Incubation at 25 °C for 40 min 
Loading Dye (µL) 2.4 2.4 2.4 2.4 
Denaturation at 95 °C for 5 min 
1Dilution 120 µM of an inhibitor in DMSO. 






Selectivity of the Activity-Based Probe 
 
Rhodesain was incubated together with or without HEK cell lysate and ABP. Four 
samples were prepared according to Table 4, each containing 200 ng of 
rhodesain, 2% of DMSO, assay buffer (50 mM sodium acetate pH 5.5, 200 mM 
NaCl, 5 mM EDTA, 0,005% Brij 35) with a total volume of 40 µL. The 
concentration of protein in HEK cell lysate was quantified by the                          
Roti®-Nanoquant protein quantification assay. 
 
Table 4. Pipetting scheme for the investigation of the selectivity of the probe. 




Rhodesain (ng) 200 200 200 200 
HEK cell lysate (µg) - 4 4 - 
DMSO (µL) 0.8 0.8 - - 
ABP1 - - 0.8 0.8 
Assay buffer (µL) Ad 40 Ad 40 Ad 40 Ad 40 
Incubation for 1 hour 
Loading dye (µL) 8 8 8 8 
Denaturation at 95 °C for 5 min 
11000 µM in DMSO. 
 
5.3.6. PROTEIN QUANTIFICATION 
 
Roti®-Nanoquant protein quantification assay was used to determine the 
concentration of a protein in HEK cell lysate. Roti®-Nanoquant solution (5-times 
conc.) had been diluted with water and 800 µL of the resulting solution was 
pipetted into 10 cuvettes. Different amounts of albumin (0.2-20 µg) were pipetted 
into 9 of them, completed with water until 1000 µL. Into the last cuvette, 2 µL of 
the HEK cell lysate and 198 µL of water were pipetted. A reference cuvette was 
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filled with 1000 µL of distilled water only (Carl Roth GmbH + Co. KG 2017). 
The calibration line was measured spectrophotometrically on a Cary 50 Bio, 
Varian at the wavelengths of 450 and 590 nm. The linearity results from the ratios 
of absorbances (A[590]/A[450]). 
 
5.3.7. ANALYSIS  
 
After the separation of proteins in SDS-PAGE is finished, those that were 
fluorescently labeled can be detected by a common imaging tool, ChemiDoc by 
Bio-Rad (Hercules, USA). This device was also used to obtain pictures. 
 
5.3.8. COOMASSIE BLUE PROTEIN STAINING  
 
Coomassie Brilliant Blue is an organic dye used to stain proteins by formation of 
stable blue complex with basic amino acids (Simpson 2010). This dye is used 
especially after SDS-PAGE for visualization of the protein bands on the gel. The 
gel is stained by incubation together with acidic staining solution under gentle 
agitation on a rocker at least for two hours. At first, the entire gel is dark blue, 
therefore a destaining solution has to be applied to wash out the abundant dye. 
The destaining process on a rocker takes a little longer than staining and the 
solution should be changed several times.  
 
The staining solution is composed of Coomassie Brilliant Blue R (0.25 g), 100 mL 
of methanol, 25 mL of acetic acid and 125 mL of distilled water. 
 
The destaining solution contains 200 mL of methanol, 50 mL of acetic acid and 
200 mL of distilled water.   
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6. RESULTS AND DISCUSSION 
6.1. NIFEDIPINE-DERIVED COMPOUNDS 
 
The first group of compounds, which was tested in the course of this thesis, was 
obtained from a cooperative research group of Prof. Dr. Lhassane Ismaili from 
the University of Burgundy Franche-Comté, France.  
 
Nifedipine is the first member of dihydropyridines, the calcium antagonists, which 
are commonly used for treating patients with hypertension (Doležal et al. 2016). 
Calcium antagonists are quite popular for prescription among doctors due to their 
relatively high safety and low incidence of acute side effects. Besides well-known 
side effects, such as swollen legs or flush in the face, all members of the group 
have been reported to cause gingival hyperplasia (Nishimura et al. 2002). The 
frequencies among the group vary between 19 and 38% (Steele et al. 1994). Not 
only is the overgrowth of gums an esthetic problem, but it also causes 
complications in possible pre-existing periodontal diseases. An inflammation of 
the gum can even increase the risk of cardiovascular or cerebrovascular events 
(Wu et al. 2000). Gingival hyperplasia is a result of cathepsin L inhibition as off-
target. Cathepsin L is involved in the cleavage of (glyco)proteins of extracellular 
matrix, such as fibronectin, collagen or laminin (Ramon et al. 1984) and its 
suppression leads to the excess of the extracellular matrix in gingiva.  
 
Besides that, a propargyl moiety on a substrate peptide or protein has been 
proven to react with the active-site cysteine nucleophile of target proteases, 
forming a vinyl thioether linkage. Interestingly, it does not react with another 
cysteine residues or thiol groups (Ekkebus et al. 2013). 
 
To obtain the percentages of remaining enzyme activities (RA), cathepsins B and 
L were assayed spectrophotometrically, whereas cathepsins K and S 
fluorometrically. The concentration of inhibitor in tested solutions was 50 µM. The 
measurements were always performed in duplicates and followed for 60 minutes. 
The mean values of remaining enzyme activities are reported in Table 5. 
Determination of Ki values was performed in cases of RA lower than 60%.  
 44 
Table 5. Enzyme inhibition by nifedipine-derived compounds. 
 Structure 
Remaining enzyme activity at 50 µM of 
inhibitor (%) 
















































































































































































NI 83 86 70 
aNo inhibition, refers to a remaining enzyme activity higher than 95%.  
Surprisingly, no inhibitors of cathepsin L were discovered. Cathepsin B and K 
also remained uninhibited, as well as cathepsin S in most cases. Compounds 10 
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and 16 exhibited a weak inhibitory potency against cathepsin S with the remaining 
activities of 54% and 58%, respectively. Hence, these two compounds were 
further investigated in concentration dependent measurements. The progress 
curves are shown in Figure 10 and Figure 11.  
 
 
Figure 10. Inhibition of cathepsin S by 10. 
Left: Monitoring of the hydrolysis of fluorogenic substrate Z-Phe-Arg-AMC          
(40 µM) in the presence of increasing inhibitor concentrations (● 0 µM; ● 20 µM; 
● 40 µM; ● 60 µM; ● 80 µM; ● 100 µM). Right: Plot of steady-state velocities of 
the substrate hydrolysis versus increasing concentrations of 10. The 
measurements were performed in duplicates and followed for 60 minutes. Non-
linear regression (Figure 5b) gave the IC50 value of 96.22 ± 12.80 µM. The Ki 
value of 55.30 ± 7.35 µM was calculated from the obtained IC50 value using the 








































Figure 11. Inhibition of cathepsin S by 16. 
Left: Monitoring of the hydrolysis of fluorogenic substrate Z-Phe-Arg-AMC 
(40 µM) in the presence of increasing inhibitor concentrations (● 0 µM; ● 20 µM; 
● 40 µM; ● 60 µM; ● 80 µM; ● 100 µM). Right: Plot of steady-state velocities of 
the substrate hydrolysis versus increasing concentrations of 16. The 
measurements were performed in duplicates and followed for 60 minutes. Non-
linear regression (Figure 5b) gave the IC50 value of 120.64 ± 9.06 µM. The Ki 
value of 69.33 ± 5.21 µM was calculated from the obtained IC50 value using the 
Cheng-Prusoff equation (Figure 5c). 
 
The compounds 10 and 16 were found to act as weak inhibitors of cathepsin S 
with Ki values of 55.30 ± 7.35 and 69.33 ± 5.21 µM, respectively. Since the 
progress curves showed linear dependency, both substances can be considered 
reversible inhibitors. Besides the basic structure, which is present in the whole 
tested group, these two compounds do not share any similarities in the variable 

































6.2. CATHEPSIN K INHIBITORS AND ACTIVITY-BASED PROBES  
 
The second series of tested compounds was synthesized for the inhibition of 
cathepsin K by Dominik Brajtenbach, the member of Prof. Gütschow’s group. The 
compounds act as peptidic Michael acceptors, since they contain a vinyl 
sulfonamide in their structures (Table 6). Instead of the scissile bond of the 
natural substrate, there is an α,β-unsaturated amide warhead. The β-carbon is 
electron-poor, thus attracts the active-site cysteine for a nucleophilic attack. The 
substituted vinyl sulfone moiety has been proven to selectively interact with the 
active-site cysteine of cysteine cathepsins and remain sufficiently inert without 
the target (Palmer et al. 1995). L-leucine has been found to be favorable in P2 
position of the inhibitor for the inhibition of cathepsin K and to a lesser extent also 
for cathepsin L and S (Bromme et al. 1996). In compounds 18 and 20, the terminal 
amine bears tert-butyloxycarbonyl (Boc), which is a protecting group, stable 
towards most nucleophiles and bases (Felix et al. 2004). Compounds 19 and 21 
contain cyanine-5, which is a fluorescent dye used for labeling purposes in 
activity-based probes (Waggoner 2006). An activity-based probe is an inhibitor 
which covalently binds into the catalytic site and contain a fluorescent or 
radioactive reporter, allowing for a direct detection of the active enzyme (Frizler 
2012).  
 
Assays were performed with four different human cathepsins, i.e., B, L, K and S, 
and a chromogenic substrate, in the presence of compounds 18-21. As 
anticipated, the substances exhibited the highest inhibitory potency against 
cathepsin K, however inhibited also the other enzymes. 
 
The compounds were assayed using spectrophotometric methods on a Cary 50 
Bio, Varian at 405 nm. For determination of remaining enzyme activity, a 
screening at 2.5 µM inhibitor concentration was performed. All measurements 
were realized in duplicates and followed for 60 minutes. The mean values of 





Table 6. Remaining enzyme activity when using vinyl sulfonamide derivatives. 
 Chemical structure 
Remaining enzyme activity at 
2.5 µM of inhibitor (%) 






















































85 69 18 NI 
aNo inhibition, refers to a remaining enzyme activity higher than 95%.  
 
Compounds which at 2.5 µM caused the remaining activity of less than 70% were 
further investigated. Concentration-dependent measurements were performed 
with 6 or 10 different concentrations of each tested compound, including the blank 
sample. The graphical representations of some of them are depicted in the 
following figures (Figure 12-15).  
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The highest inhibitory potency exhibited the activity-based probe 19 against 
cathpesin K with the second-order rate constant (kinact/Ki) of 3 357 ±                            
1 232 M-1s-1, while retaining the selectivity at least 3.8-fold higher over other 
cathepsins. The progress curves are shown in Figure 12. More values together 
with their standard errors are reported in Table 7. 
 
 
Figure 12. Inhibition of cathepsin K by 19. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (100 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 0.4 µM; ● 0.8 µM; ● 1.2 µM; 
● 1.6 µM; ● 2 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of 19. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 
of 3 357 ± 1 232 M-1s-1 according to equation d in Figure 5. 
 
Table 7. The second-order rate constants (kinact/Ki) of cathepsin K and S when 
inhibited by compounds 18-21. 
 kinact/Ki (M-1s-1) 
 Cathepsin K Cathepsin S 
18 953 ± 258 482 ± 104 
19 3 358 ± 1232 876 ± 696 
20 - 188 ± 201 
21 383 ± 229 - 
 






























The compound 21 caused a different type of inhibition of cathepsin L than the 
one observed in other cases. The progress curves showed linear dependency 
(Figure 13), i.e., the inhibition is not time-dependent. Therefore, the compound 
can be considered a reversible inhibitor and has to be evaluated in a different 
manner. 
 
Figure 13. Inhibition of cathepsin L by 21. 
Monitoring of the hydrolysis of Z-Phe-Arg-pNA (100 µM) in the presence of 10 
increasing inhibitor concentrations, including the blank sample (● 0 µM; ● 0.5 µM; 
● 1 µM; ● 1.5 µM; ● 2 µM; ● 2.5 µM; ● 3 µM; ● 3.5 µM; ● 4 µM; ● 4.5 µM; ● 




Figure 14. Plot of steady-state velocities of the substrate hydrolysis versus 
increasing concentrations of 21, using the equation a in Figure 5. 
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Since the data points do not make up the typical shape of the progress curve and 
non-linear regression following equation a in Figure 5 does not seem reasonable, 
there must be some interaction in the enzymatic reaction. The enzyme does not 
react with the substrate in a ratio of 1:1. Therefore, the stoichiometric parameter 
(x) has been applied into equation a in Figure 5., resulting in the so-called three-
parameter equation (Figure 5b). The corrected plot is shown in the next figure 
and the results in numbers are shown in Table 8. 
 
 
Figure 15. Corrected plot of steady-state velocities of the substrate hydrolysis 
versus increasing concentrations of 21, using the equation b in Figure 5. 
 
Table 8. Kinetic evaluation of 21. 
 Two-parameter model Three-parameter model 











21 1.97 ± 0.73 1 0.29 ± 0.11 2.78 ± 0.04 4.96 0.40 ± 0.01 
 
In this series, the most significant inhibitory potency against cathepsin K exhibited 
compound 19, whose progress curves were pointing to the irreversible mode of 
binding. Its second-order rate constant (kinact/Ki) was 3 357 ± 1 232 M-1s-1 and the 
selectivity for cathepsin K was at least 3.8-fold higher over other cathepsins. The 
compound is an activity-based probe, bearing the fluorescent dye, cyanine-5, in 
its structure, hence could be used for labeling purposes in the future.  
[21] (µM)












Moreover, the compounds containing cyanine-5 in their structure showed a 
greater inhibitory potency against all of the tested proteases if compared to the 
substances bearing tert-butyloxycarbonyl instead. This could indicate that 
cyanine-5 increases the inhibitory activity.  
 
The measurements also revealed a distinctive behavior of the compound 21. The 
reversible binding mode against cathepsin L with an unknown interaction in the 
enzymatic reaction has been observed. Therefore, a stoichiometric parameter 
has been inserted into the classical equation for IC50 determination (Figure 5a), 
resulting in the so-called three-parameter equation (Figure 5b), leading us to the 
IC50 value corrected with the factor (1+[S]/KM) of 0.40 ± 0.01 µM compared to 
0.29 ± 0.11 µM, when using the simple two-parameter equation.  
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6.3. RHODESAIN  
 
The enzyme gathering the most attention within this work is called rhodesain. It 
was expressed and purified by Dr. Patrick Johe from the group of Prof. Dr. Tanja 
Schirmeister at the University of Mainz in Germany, as described in Caffrey et al. 
(2001).  
 
At first, since it had not been tested by anyone else at our institute on a 
spectrophotometer, the Michaelis-Menten value (KM) has to be established for 
the specific assay conditions. Knowing the KM value allows us to define possible 
inhibitors and their selectivity for rhodesain over other enzymes.  
 
6.3.1.  MICHAELIS-MENTEN VALUE  
 
Caffrey et al. (2001) described the use of the fluorogenic substrate                                
Z-Phe-Arg-NMec (7-amido-4-methylcoumarin) in assays with rhodesain. In the 
course of this thesis, the activity of rhodesain was monitored by hydrolysis of the 
chromogenic substrate Z-Phe-Arg-pNA in spectrophotometric assays carried on 
a Cary 50 Bio, Varian at 405 nm and 25 °C in cuvettes. The enzyme (4 mg/mL in 
10 mM sodium citrate buffer pH 5.0) was preincubated with the activation buffer 
containing 50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM EDTA and 2 mM 
DTT (Klein et al. 2020) in a dilution of 1:850 at 25 °C for 30 min. The tested 
solution contained 960 µL of the assay buffer consisting of 50 mM sodium acetate 
pH 5.5, 200 mM NaCl, 5 mM EDTA and 0,005% Brij 35 (Klein et al. 2020), a range 
of substrate concentrations between 1 and 50 µM, 2% DMSO and 20 µL of the 
enzyme. The measurements were followed for 10 minutes in triplicate. 
 
The KM value of 3.9 ± 0.6 µM was calculated with the Michaelis-Menten equation 
(Figure 6a), using means of obtained steady-state velocities plotted versus 
increasing substrate concentration. The Michaelis-Menten value was verified by 
using Hanes-Woolf plot. The linear regression gave the KM value of 3.7 ± 0.6 µM. 
Lineweaver-Burk plot, which is more prone to error, gave the KM value of 7.7 ± 


































Figure 16. A) Michaelis-Menten; B) Hanes-Woolf; C) Lineweaver-Burk plot.  
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6.3.2. OPTIMIZATION OF ASSAY CONDITIONS 
 
The perfect testing solutions for the assay contain the concentration of the 
substrate that far exceeds the amount of the enzyme, thus the reaction rate is 
independent of substrate concentration (Kramer 1980). The enzyme amount is 
optimal when it does not consume more than 10-20% of the substrate, but it can 
still provide us with a sufficient read-out signal (Wu et al. 2003).  
 
Several assays with various enzyme and substrate concentrations have been 
performed while maintaining constant amounts of other components. The 
solutions containing 23.5 ng (5 µL) of rhodesain and 40 µM of the substrate 
appear to be ideal. The concentration of DMSO is 2% and the rest is constituted 
by the assay buffer. The total volume in each cuvette is 1 mL. 
 
6.3.3. INHIBITION OF RHODESAIN BY E-64 
 
The inhibitory potency of the reference inhibitor E-64 against rhodesain was 
determined next to prove the appropriate and stable assay conditions. E-64 is a 
widely used, potent inhibitor of several cysteine proteases, which inhibits in an 
irreversible manner. It has been first isolated and identified from a culture of 
Aspergillus japonicus (Hanada et al. 1978). Since E-64 inactivates wide range of 
cysteine proteases, the mechanism has been extensively investigated and new 
inhibitors can be developed based on the structure of E-64. The structure consists 
of a trans-epoxysuccinic acid attached to a dipeptide. A common feature is a 
covalent bond formation between the epoxy carbon of the inhibitor and sulfur of 
the active-site cysteine (Varughese et al. 1989). The inhibition occurs via 
nucleophilic attack, which is a crucial information for uncovering the inhibitory 
activity (Matsumoto et al. 1999). Progress curves of rhodesain in the presence of 
different inhibitor concentrations are shown in Figure 17. For comparison with 





Figure 17. Inhibition of rhodesain by E-64. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (40 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 0.2 µM; ● 0.4 µM; ● 0.6 µM; 
● 0.8 µM; ● 1 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of E-64. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 
of 146 654 ± 82 760 M-1s-1, using the equation d in Figure 5.  
 
 
Table 9. Comparison of inhibitory potency of E-64 against selected cysteine 
proteases. 
aMeasurements and the kinetic evaluation were performed by Carina Lemke. 
 
As expected, rhodesain is inhibited as well as other cysteine proteases because 
E-64 is a pan-cysteine protease inhibitor.  
t (min)














 Chemical structure 
kinact/Ki (M-1s-1) 
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6.3.4. SCREENING OF A SMALL COMPOUND LIBRARY AS POTENTIAL 
INHIBITORS FOR RHODESAIN 
 
A small library of compounds was tested for rhodesain inhibition, all bearing a 
thiophene moiety directly attached to a heterocyclic system, in order to find new 
potential lead compounds for the discovery of rhodesain inhibitors. 
Spectrophotometrical assays were performed with 5 µM of the potential inhibitor. 
The measurements were followed for 60 minutes. Unfortunately, none of them 
has shown significant inhibition. Moreover, compounds 34 and 37 were even very 
poorly soluble under testing conditions, resulting in precipitation. When using 
lower concentration (3 µM), no inhibition was observed. Structures of the 
compounds and means of the remaining enzyme activities from duplicate 
measurements are reported in Table 10. 
 
Table 10. Inhibition of rhodesain by heterocyclic compounds. 
 Chemical structure 
Remaining enzyme activity    

































































































































aNo inhibition, refers to a remaining enzyme activity higher than 95%.  
bPrecipitated at 5 µM, thus measured at 3 µM.  
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6.3.5. INHIBITION OF RHODESAIN BY PHENYL VINYL SULFONES 
 
The following substances were synthesized for rhodesain by Carina Lemke and 
Dr. Matthias Dieter Mertens. The structures always contain a peptidic backbone 
with an electrophilic phenyl vinyl sulfone warhead, which acts as the Michael 
acceptor and selectively interacts with the active-site cysteine of cysteine 
cathepsins. Compound 36 bears a phenylalanine moiety in P2 position, proven 
to be beneficial for rhodesain inhibition (Giroud et al. 2018). To increase 
selectivity towards rhodesain, compounds 37 and 38 incorporate meta and para-
substitutions at the phenyl ring of the P2 amino acid (Jaishankar et al. 2008). 
In compounds 36-38, the terminal amine of the phenylalanine bears tert-
butyloxycarbonyl (Boc), which is a protecting group, stable towards most 
nucleophiles and bases (Felix et al. 2004), whereas in compounds 39 and 40, 
there is a fluorophore, making them potential activity-based probes. Chemical 




Table 11. Kinetic evaluation of inhibitory potency of 36-40. 
 Chemical structure 
kinact/Ki (M-1s-1) 
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± 10 929 
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± 2 761 



















16 387    
± 1 395 
21 257   
± 3 899 
75 207 ± 


















405        
± 69b 



















364   
± 65b 
6 239 
± 5 240b 
19 858 
± 3 294b 
43 258 
± 26 343b 
26 102 
± 7 495 
Cat – cathepsin; Rhod – rhodesain 
aMeasurements were performed by Dr. Janina Schmitz and evaluated by Duyen 
Dao. 
bMeasurements and the kinetic evaluation were performed by Carina Lemke. 
c39 behaved as a slow-binding inhibitor, evaluation was performed according to 
equations f-i in Figure 5. 
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The greatest inhibitory potency against rhodesain exhibited peptidomimetic 
inhibitor 36, containing unsubstituted phenyl of phenylalanine and Boc protecting 
group. Its second-order rate constant was 135 948 ± 87 605 M-1s-1 according to 
equation d in Figure 5, which is nearly equal to the (kinact/Ki) of reference inhibitor 
E-64 (146 654 ± 82 760 M-1s-1). The selectivity of 36 for rhodesain was at least 
17-fold higher over other cathepsins. 
 
  
Figure 18. Inhibition of rhodesain by 36. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (40 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 0.015 µM; ● 0.03 µM; ● 0.045 µM; 
● 0.06 µM; ● 0.075 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of 36. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 
of 135 948 ± 87 605 M-1s-1 according to equation d in Figure 5. 
 
Two derivatives of the previous compound with substitutions on the phenyl ring 
of the phenylalanine in P2 position were tested on rhodesain and other enzymes. 
Compound 37 contains a methyl group in para position and the compound 38 
offers chlorine in meta position. Both of them have shown a significant inhibitory 
potency against rhodesain, however, compound 37 exhibited a higher selectivity. 
The second-order rate constants (kinact/Ki) are 74 662 ± 147 418 M-1s-1 and      
75 207 ± 131 918 M-1s-1 for compounds 37 and 38, respectively. Higher errors 
are caused by the use of inhibitor concentrations, which are way lower than the 
inhibitory constant. When plotting the first-order rate constants (kobs) versus 
increasing concentrations of the inhibitor, the curve is flatter (e.g., Figure 19 and 
Figure 22), and therefore, the second-order rate constant is more difficult to 
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estimate, resulting in a reduced accuracy. The selectivity of 37 for rhodesain is 
4.8 times higher over other cathepsins, whereas the one of 38 just 3.5 times. The 
values could indicate, that the substitution on the phenylalanine causes decrease 
in inhibitory potency, however, the remaining enzyme activities of rhodesain, if 
inhibited by compounds 37 and 38 at a concentration of 10 µM, were little lower 
than the RA in case of compound 36, even though they were all around 0. 
Progress curves of the activity of various enzymes when using the compound 37 




Figure 19. Inhibition of rhodesain by 37. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (40 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 0.04 µM; ● 0.08 µM; ● 0.12 µM; 
● 0.16 µM; ● 0.2 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of 37. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 
of 74 662 ± 147 418 M-1s-1, using the equation d in Figure 5.  
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Figure 20. Inhibition of cathepsin B by 37. 
Left: Monitoring of the hydrolysis of Z-Arg-Arg-pNA (500 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 2 µM; ● 4 µM; ● 6 µM; ● 8 µM; 
● 10 µM). Right: Plot of the first-order rate constants (kobs) versus increasing 
concentrations of 37. The measurements were performed in duplicates. Non-
linear regression gave the second-order rate constant (kinact/Ki) of 160.54 ± 




Figure 21. Inhibition of cathepsin K by 37. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (100 µM) in the presence of 
increasing inhibitor concentrations: (● 0 µM; ● 2.5 µM; ● 5 µM; ● 7.5 µM; ● 10 µM; 
● 12.5 µM). Right: Plot of the first-order rate constants (kobs) versus increasing 
concentrations of 37. The measurements were performed in duplicates. Non-
linear regression gave the second-order rate constant (kinact/Ki) of 445.12 ± 






































































Figure 22. Inhibition of cathepsin L by 37. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (100 µM) in the presence of 
increasing inhibitor concentrations: (● 0 µM; ● 0.16 µM; ● 0.32 µM; ● 0.48 µM; 
● 0.64 µM; ● 0.8 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of 37. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 




Figure 23. Inhibition of cathepsin S by 37. 
Left: Monitoring of the hydrolysis of Z-Phe-Val-Arg-pNA (70 µM) in the presence 
of increasing inhibitor concentrations (● 0 µM; ● 0.3 µM; ● 0.6 µM; ● 0.9 µM; 
● 1.2 µM; ● 1.5 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of 37. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 
of 15 461 ± 2 761 M-1s-1, using the equation d in Figure 5. 
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Compounds 39 and 40 are potential activity-based probes with the unsubstituted 
phenylalanine and coumarin as the fluorophore in their structure. The analysis of 
the inhibition mode of compound 39 has clearly revealed the slow-binding 
behavior (seen in Figure 24), which is characterized by an initial exponential 
phase, followed by a linear steady-state equilibrium. This is hardly explainable, 
since Michael acceptors are prone to undergo irreversible inhibition. This type of 
time-dependent inhibition needs to be evaluated in a different manner, described 
by the association (kon) and the dissociation constant (koff), in addition to the 
inhibition constant (Ki). Results obtained using equations f-i in Figure 5 are 
shown in Table 12. Due to the non-complete irreversibility, compound 39 is not 
the preferred candidate for activity-based probing, in contrast to 40, which seems 
to inhibit rhodesain with full irreversibility. Compound 40 acts as a reasonable 
inhibitor of rhodesain. Non-linear regression gave the second-order rate constant 
(kinact/Ki) of 26 102 ± 7 495 M-1s-1, according to equation d in Figure 5. With regard 
to different inhibition modes of these two compounds, their inhibitory potency is 
not directly comparable. Nevertheless, remaining enzyme activity of rhodesain in 
a solution with 10 µM of inhibitor was 20% in case of compound 39 and 0% for 
40. Although compound 40 was not very selective for rhodesain, and cathepsin 
S was even better inhibited, this probe was a satisfactory starting point for in-gel 
detection of rhodesain. 
 
 
Figure 24. Inhibition of rhodesain by 39. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (40 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 0.6 µM; ● 1.2 µM; ● 1.8 µM; 
● 2.4 µM; ● 3 µM). Right: Plot of steady-state velocities versus increasing 
concentrations of 39. The insert is a Dixon plot showing a linearity.  
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Table 12. Kinetic evaluation of slow-binding behavior of 39. 
 kon (M-1s-1) koff (10-4s-1) Ki (nM) 




Figure 25. Inhibition of rhodesain by 40. 
Left: Monitoring of the hydrolysis of Z-Phe-Arg-pNA (40 µM) in the presence of 
increasing inhibitor concentrations (● 0 µM; ● 0.16 µM; ● 0.32 µM; ● 0.48 µM; 
● 0.64 µM; ● 0.8 µM). Right: Plot of the first-order rate constants (kobs) versus 
increasing concentrations of 40. The measurements were performed in 
duplicates. Non-linear regression gave the second-order rate constant (kinact/Ki) 
of 26 102 ± 7 495 M-1s-1, according to equation d in Figure 5. 
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6.3.6. PROBE APPLICATION IN SDS-PAGE ANALYSIS 
 
Since the compound 40 has shown a significant inhibitory potency against 
rhodesain and contains a fluorophore in its structure, it was then further 
investigated in SDS-PAGE analysis. Compound 39 possesses the fluorophore as 
well, but the inhibition of rhodesain was not as potent nor convenient. The 
purpose of these assays was to show the selectivity of labeling by the probe, 
which could then be used for a protein identification and profiling.  
 
Initially, to identify the enzyme in the gel and find its ideal concentration, the 
electrophoresis with various concentrations of the enzyme was performed.  
 
In the first experiment, rhodesain was incubated with the activation buffer, 
containing 50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM EDTA and 2 mM 
DTT for 30 minutes at 25 °C. Decreasing amounts of the enzyme (500, 250, 200, 
150, 100, 50 ng) were treated with 20 µM of 40, 2% of DMSO and activation 
buffer with total volume of 40 µL in micro-reaction vessels. Solutions were 
incubated at 25 °C for 1 hour. After that, 8 µL of purple gel loading dye was added 
into each vessel and subsequently denatured at 95 °C for 5 minutes. The blank 
sample (C) containing just the enzyme (500 ng) and no probe, but has been 
processed parallelly with other samples, serves as a control to confirm the 
efficiency of the labeling (Galmozzi et al. 2014). A molecular weight marker was 
loaded into the first gel well. Samples were carefully pipetted into their dedicated 
wells. Thereafter, a voltage of 120 V was applied until the loading dye reached 
approximately 1.5 cm from the end. The gel was then analyzed using a common 
gel documentation device, ChemiDoc by Bio-Rad, and after that stained with the 
Coomassie Blue staining solution (Figure 26). The assay conditions were 





Figure 26. SDS-PAGE with decreasing concentrations of rhodesain and DTT. 
Left: ChemiDoc detection image, excitation wavelenght 485 nm, emission 
wavelenght 515 nm. Right: Coomassie Blue staining.  
C – 500 ng; I – 500 ng; II – 250 ng; III – 200 ng; IV – 150 ng; V – 100 ng;          
VI – 50 ng of rhodesain, which was preincubated with the activation buffer. All 
samples except the first, control sample, contain an abundant amount (20 µM) of 
compound 40.  
 
With the use of this method, successful labeling could not be detected besides 
an unknown band, which was present over the entire width of the gel. The gel 
was additionally stained with Coomassie Blue and neither then anything could be 
seen. 
 
The concentration assay was repeated with different assay conditions, adapted 
from Mertens et al. (2014). The enzyme was not treated with the activation buffer, 
whereas directly pipetted into micro-reaction vessels containing the assay buffer 
(50 mM sodium acetate pH 5.5, 200 mM NaCl, 5 mM EDTA, 0,005% Brij 35), 20 
µM of compound 40 and 2 µL of DMSO, with the total volume of 12 µL. Solutions 
were incubated at 25 °C for 1 hour. After that, 2.4 µL of the purple gel loading dye 
was pipetted into each vessel and the solutions were subsequently denatured at 
75 °C for 10 minutes. A molecular weight marker was loaded into the first gel well. 
Samples were carefully pipetted into their dedicated wells. Thereafter, a voltage 
of 120 V was applied until the loading dye reached approximately 1.5 cm from 
the end. The gel was then analyzed using a common gel documentation device, 
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ChemiDoc by Bio-Rad, and after that stained with the Coomassie Blue staining 
solution (Figure 27). 
 
Figure 27. SDS-PAGE with decreasing concentrations of the enzyme. 
Left: ChemiDoc detection image, excitation wavelenght 485 nm, emission 
wavelenght 515 nm. Right: Coomassie Blue staining. 
C – 500 ng; I – 500 ng; II – 250 ng; III – 200 ng; IV – 150 ng; V – 100 ng;          
VI – 50 ng of rhodesain. All samples except the first, control sample, contain 
20 µM (abundance) of compound 40.  
 
In this gel, we can see a band of the fluorescently labeled rhodesain weakening 
with the enzyme concentration at approximately 25 kDa. This size corresponds 
to the actual size of the active rhodesain, which is approximately 23 kDa (The 
UniProt Consortium 2020). The limit concentration for detection rhodesain is 100 
ng. The ideal rhodesain concentration, which shows the strong fluorescent band 
of rhodesain but does not exceed the saturation of the enzyme by the probe, yet, 
is 500 ng. 
 
The gel was additionally stained with Coomassie Brillant Blue and nothing could 
be seen, which indicates that the fluorescent method is more sensitive. 
 
The feasibility of direct in-gel fluorescence detection was proven to be successful, 
after the treatment of rhodesain with 40, together with the establishment of the 
minimal and the ideal enzyme concentration and detection of the rhodesain 
molecular weight. The following step was to confirm the binding mode of 40. The 
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competition experiment with the active-site-directed inhibitor E-64 was 
performed.  
 
The first SDS-PAGE competition assay was performed parallelly and under the 
same conditions as the first SDS-PAGE assay with various enzyme 
concentrations, adapted from Frizler et al. (2013). As in the first SDS-PAGE 
experiment shown in this thesis (Figure 26), also here the main fluorescent band 
is caused by an unknown element and is present over the entire width of the gel. 
Besides that, nothing was detected (Figure 28). 
 
 
Figure 28. SDS-PAGE competition assay of E-64 and 40 with DTT. 
Left: ChemiDoc detection image, excitation wavelenght 485 nm, emission 
wavelenght 515 nm. Right: Coomassie Blue staining. 
I – negative control; II – E-64; III – E-64, 40; IV – 40. All samples contain 500 ng 
of rhodesain. Concentration of each inhibitor in the sample is 20 µM. 
 
The next experiment was performed with the same assay conditions as in the 
successful experiment without previous activation of rhodesain, adapted from 




Figure 29. SDS-PAGE competition assay of E-64 and 40. 
Left: ChemiDoc detection image, excitation wavelenght 485 nm, emission 
wavelenght 515 nm. Right: Coomassie Blue staining.  
I – negative control; II – E-64; III – E-64, 40; IV – 40  
All samples contain 500 ng of rhodesain. Concentration of each inhibitor in the 
sample is 20 µM. 
 
A strong fluorescent band was observed in both samples containing rhodesain 
and activity-based probe 40. The fact, that rhodesain is fluorescently labeled also 
in the sample, which was preincubated with active-site-directed, covalent-binding 
inhibitor, E-64, does not confirm the proposed hypothesis of covalent binding of 
compound 40 into the active-site of the enzyme. Nevertheless, it cannot be 
disapproved, because it is still possible, that 40 interacts with the surface 
nucleophiles of the protein and also with the active-site, if free. 
 
The last experiment was performed to find out whether our compound is 
a selective inhibitor or a promiscuous binder. Compound 40 was applied to label 
rhodesain in the mixture with a complex proteome, lysate from human embryonic 
kidney 293 cells (HEK cell) provided by Martin Mangold. Rhodesain (200 ng) was 
incubated at 25 °C in 4 aliquots containing 2% DMSO, assay buffer (50 mM 
sodium acetate pH 5.5, 200 mM NaCl, 5 mM EDTA, 0,005% Brij 35) together with 
or without HEK cell lysate (4 µg) and 40 (20 µM) with the total volume of 40 µL. 
After 1 hour, 8 µL of the loading dye was added into the solutions and all of them 
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were denatured at 95 °C for 5 minutes. The samples were carefully pipetted into 
gel wells. Thereafter, a voltage of 120 V was applied until the loading dye reached 
approximately 1.5 cm from the end. The gel was then analyzed using ChemiDoc 
by Bio-Rad. The assay conditions were adapted from Frizler et al. (2013) and 
Mertens et al. (2014). The concentration of protein in HEK cell lysate was 
quantified by the Roti®-Nanoquant protein quantification assay. 
 
In rhodesain, compound 40 has bound into its usual place, but in the sample 
where rhodesain is in the mixture with the proteins of HEK cell lysate, the 
compound has bound unspecifically to several other proteins rather than to 
rhodesain (Figure 30, lane III). The gel has been additionally stained with 
Coomassie Blue. Only proteins of HEK cell lysate, which were used in a 
significant abundance compared to the amount of rhodesain, are visible. This 
experiment unfortunately proves, that the compound 40 cannot be used as a 
reporter of rhodesain nor its inhibitor in human, because there are several other 
proteins, which would react with this probe. 
 
 
Figure 30. Imaging of rhodesain with the fluorescent probe 40 in the presence of 
HEK cell lysate. 
Left: ChemiDoc detection image, excitation wavelenght 485 nm, emission 
wavelenght 515 nm. Right: Coomassie Blue staining. 
I – negative control; II – HEK cell; III – HEK cell, 40; IV – 40.  
All samples contain 200 ng of rhodesain. Concentration of the inhibitor is 20 µM. 
The amount of HEK cell lysate in a sample was 4 µg. 
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Further efforts should be made to prepare an activity-based probe for this 
protozoal cathepsin, as it may help to understand the disease mechanism better, 
through the visualization of the enzyme in native material. One of possible 
improvements could be a more specific inhibitor with, e.g., different irreversible 
warhead. Another possibility is to change incubation conditions or read-out 
modality. 
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7. CONCLUSION  
 
In summary, two weak, reversible inhibitors (10 and 16) of cathepsin S, which do 
not share any similarities in variable substituents, have been revealed among 
nifedipine derivatives.  
 
Some inhibitors of cathepsin K have been discovered. The most potent one was 
the compound 19, which is a peptidic Michael acceptor bearing a fluorophore. 
This compound consists of a substituted vinyl sulfonamide warhead, L-leucine in 
P2 position and a fluorescent dye, cyanine-5, hence, could be further investigated 
as an activity-based probe for cathepsin K. 
 
The compound 21 has been identified as a reversible inhibitor of cathepsin L. For 
the kinetic evaluation, a stoichiometric paremeter, correcting the plot of steady-
state velocities of the substrate hydrolysis against increasing concentrations of 
the inhibitor was used, resulting in the so-called three-parameter model. 
 
The Michaelis-Menten value for spectrophotometric assays with rhodesain has 
been stated to 3.9 ± 0.6 µM under the herein reported assay conditions for the 
substrate Z-Phe-Arg-pNA. 
 
The inhibitory potency of the reference inhibitor E-64 against rhodesain has been 
determined. The second-order rate constant (kinact/Ki) is 146 654 ± 82 760 M-1s-1. 
 
The compound 36 inhibits rhodesain to almost the same extent as E-64, while 
being highly selective. This peptidic Michael acceptor bears an electrophilic vinyl 
sulfone warhead and phenylalanine in P2 position, with the terminal amine 
protected by tert-butyloxycarbonyl (Boc). Its derivatives, compounds 37 (methyl 
in para position) and 38 (chlorine in meta position) have a lower kinact/Ki with a 
higher systematic error, but the remaining enzyme activities when using 10 µM 




Two activity-based probes for rhodesain were investigated. The compound 39 
has exhibited slow-binding behavior and has been evaluated using appropriate 
parameters. Compound 40 was chosen to be used as an activity-based probe in 
sodium dodecyl sulfate polyacrylamide gel electrophoresis for labeling purposes 
of rhodesain. This compound has shown that it cannot be used in activity-based 
proteomics for rhodesain, because of being a promiscuous binder. However, the 
assay conditions have been improved and will be prepared for the next potential 








































































































Figure 31. Discussed structures.  
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